Specialized Diagnostics Metamark's focus on innovative prostate and urologic cancer diagnostics, notably the ProMark™ test, presents an opportunity to expand sales efforts in urology clinics and oncology centers seeking advanced prognostic tools.

Growth Milestones Having launched ProMark successfully across the nation and demonstrated cost-effective care through published studies, the company is poised for further market penetration and potential expansion into other cancer testing markets.

Financial Potential With revenues ranging between 10 to 25 million and significant funding of 13 million dollars, Metamark is financially positioned to invest in sales and marketing expansions targeting top-tier clinical laboratories and healthcare providers.

Technological Edge Utilizing a robust tech stack and proven proteomic testing platforms, Metamark offers scalable and reliable diagnostic solutions, appealing to research institutions interested in integrating cutting-edge molecular diagnostics.

Market Positioning As a dedicated leader in clinical proteomics and uro-oncology diagnostics, Metamark can leverage its scientific credibility and published evidence to build partnerships with hospital systems, academic clinics, and private practices focused on personalized cancer treatment.